Foghorn Therapeutics Inc (FHTX)

Foghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026

WATERTOWN, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a...

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May

WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update

- FHD-909 (LY4050784) Phase 1 dose-escalation trial on track; preclinical combination data with anti-PD-1...

Form ARS - Annual Report to Security Holders

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting

- Complete and durable regression and anti-tumor immune memory following treatment with FHD-909 (LY4050784) in...

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting

New preclinical data for FHD-909 (LY4050784) reinforcing the potential for expansion opportunities in...

Form S-8 - Securities to be offered to employees in employee benefit plans

Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook

FHD-909 (LY4050784) Phase 1 dose-escalation advancing as planned, targeting SMARCA4 (BRG1)-mutant cancers with...

Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences

WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a...